On July 30, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Since the COVID-19 coronavirus stay-at-home orders were issued in March 2020, the future has been difficult to imagine. National professional meetings, including ONS Congress, graduations, weddings, funerals, and other events that mark the transition from present to future were canceled. Creative, alternative ways to mark a transition to the future are highlighted on social media and the nightly news. Virtual, Zoom, and the new normal are standard verbiage in our conversations.
The Oncology Nursing Society’s (ONS’s) books, journals, and news magazine have a long history of industry recognition, receiving numerous awards for their commitment to excellence in publishing. This month, Association Media and Publishing, Association Trends, and Communication Concepts, Inc., added new distinctions to the ONS publishing portfolio.
Half of all healthcare professionals have started using telemedicine in response to the COVID-19 coronavirus pandemic. Patients and providers are trying to adjust to such rapid changes in the provision of health care. Providers want to know how to get reimbursement for telemedicine visits. Society is working together to answer the critical questions about this next wave of health care.
When it comes to the human brain, the ability to effectively multitask is a myth. Although computers can run two or more programs simultaneously, our brains must task-switch, and in the transfer of attention, time and productivity are lost. Monotasking, or single tasking, is now considered a way to increase productivity and actually maximize time.
Users of two common antihistamines—desloratadine and loratadine—have lower mortality rates from cutaneous malignant melanoma than patients who use other antihistamines, researchers reported in Allergy.
As one of the only not-entirely-pandemic-related health policy topics currently in policymakers’ discussions, lawmakers are again revisiting the high cost of prescription drugs. Voters have voiced concerns in the current economic climate, and, eager to appease in the months before the November presidential election, the Trump administration responded.
Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.
As one of the youngest members of the 2018 freshman congressional class, U.S. Representative Lauren Underwood (D-IL) has already made quite a name for herself. Eschewing, for the most part in this heightened environment, partisanship and instead concentrating on health and economic issues, the representative champions access and affordability for all Americans.
On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (Tecartus™), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.